Business
Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
Nurix to provide a clinical update from the ongoing Phase 1 trial of NX-2127 in patients with hematologic malignancies SAN FRANCISCO, Nov. 03, 2022 (GLOBE
About this update from Nurix Therapeutics, Inc.
[{"type":"text","content":"Nurix to provide a clinical update from the ongoing Phase 1 trial of NX-2127 in patients with hematologic malignancies\nSAN FRANCISCO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that its clinical-stage BTK degrader programs will be featured in two oral presentations and one poster presentation at the 64th American Society of Hematology Annual Meeting and Exposition being held December 10-13, 2022 in New Orleans, LA. The oral presentation by Dr. Anthony Mato of Memorial Sloan Kettering Cancer Center will include a clinical update on chronic lymphocytic leukemia patients from Nurix’s ongoing Phase 1 trial of NX-2127. Oral Presentation Details: Title: NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies Speaker: Anthony Mato, M.D., MSCE, Director of the Chronic Lymphocytic Leukemia (CLL) Program at Memorial Sloan Kettering Cancer CenterPresentation Time: 5:30 PM CTSession Name: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Drugs in Development and COVID-19 Session Date and Time: Monday, December 12, 2022, 4:30 PM - 6:00 PM CTLocation: Ernest N. Morial Convention Center, 243-245Publication Number: 965 Title: Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK DegradersSpeaker: Omar Abdel-Wahab, M.D., Director of the Center for Hematologic Malignancies at Memorial Sloan Kettering Cancer Center Presentation Time: 11:45 am CTSession Name: 641. Chronic Lymphocytic Leukemias: Basic and Translational: Novel Therapies and Biomarkers Session Date and Time: Monday, December 12, 2022, 10:30 AM - 12:00 PM CTLocation: Ernest N. Morial Convention Center, La Nouvelle Orleans Ballroom ABPublication Number: 750 Poster Presentation Details: Title: Bruton’s Tyrosine Kinase (BTK) degrader NX-2127 exhibits lethal activity and synergy with venetoclax and BET protein inhibitor against MCL cells sensitive or resistant to covalent BTK inhibitorsAuthors: Warren Fiskus, Kaberi Das, Christopher Mill, Christine Birdwell...